Structure Search


    Online Support

  •  Customer service

    Location: Industrial Info

Fighting the hepatitis B virus and exploring the

2019-07-04 来源:转载自第三方
Chronic hepatitis B is one of the most important infectious diseases that endanger the health of our people. There are currently more than 10 million chronic hepatitis B patients in China who have not yet obtained definitive diagnosis and effective antiviral treatment. Recently, the Xiangshan Science Conference held an academic seminar on the theme of “Chronic Hepatitis B Functional Cure”. In order to attack the human “old rival” of the hepatitis B virus, experts in the industry proposed new ideas, new progress and new achievements, and called for guidance on this basis clinically, to explore the "new path" to functionally cure hepatitis B.
There are three main modes of transmission of hepatitis B: blood transmission, vertical transmission of mother and child, and sexual contact. However, daily work, hugs, meals, and accommodations are generally not infected with hepatitis B. More than half of the patients with chronic hepatitis B in China are infected with mother-to-child transmission.
For the treatment of chronic hepatitis B in children aged 1-6 years, it has often been thought that children should not be treated with antiviral therapy if they are in the immune tolerance period (early stage). This clinical guideline is actually based on adult immunity. Wang Fusheng, an academician of the Chinese Academy of Sciences, said that the Fifth Medical Center of the General Hospital of the People's Liberation Army specifically aimed at the treatment of chronic hepatitis B antiviral therapy in children aged 1-6 years. The smaller the age of children aged 1-6, the greater the chance of antiviral cure, and the therapeutic effect is better than that. adult.
Experts attending the conference believe that the results of this segment of the population are based on real-world medical research, and provide a more scientific basis for the diagnosis and treatment of previous antiviral concepts, which may change the current guidelines for children with chronic hepatitis B antiviral therapy. To this end, randomized controlled trials of children with chronic hepatitis B antiviral therapy should be further stepped up to further clarify the optimal treatment options.
In addition to the new progress of the segmented population, the fight against hepatitis B virus should also be changed from “drug anti-virus” to “multi-pronged”. The medicinal aiming at the virus has achieved certain results in suppressing viral replication, but the industry generally believes that the effect is poor and difficult to cure. There should be some changes in the treatment thinking. Human beings must overcome the hepatitis B virus, not only to develop anti-virus drugs, but also to find new breakthroughs in improving the ability of the autoimmune system to resist hepatitis B virus.
At present, hepatitis B patients mainly use nucleoside analogues (lamivudine, adefovir, entecavir) in antiviral drugs. The chemical structure of nucleoside analogs is similar to that of natural nucleotides. It can make hepatitis B virus misunderstand that it is a synthetic raw material and is incorporated into the hepatitis B virus chain. The drug will block the further extension of the viral chain and inhibit the replication of hepatitis B virus.
In addition to the harm of hepatitis B virus itself, studies have shown that the body's immune function damage and immune disorders are important mechanisms leading to liver inflammation, fibrosis and liver cancer.
Therefore, the treatment of chronic hepatitis B only achieves the inhibition of hepatitis B virus replication (undetectable by DNA) is not enough, in order to achieve long-lasting surface antigen clearance, this is the goal of functional cure.
In order to achieve functional cure for hepatitis B, there is still a lot of work to be done in the future, which involves clinical diagnosis and treatment, as well as basic research on viruses and immunity, as well as research and development of related drugs, so it requires domestic and foreign clinical experts and basic experts. We hope that more new hepatitis B drugs and vaccines can be developed to completely cure hepatitis B, benefit patients with hepatitis B, inhibit the spread of hepatitis B, and help humans overcome this serious health hazard.
Related links: Adefovir
Edited by Suzhou Yacoo Science Co., Ltd.


Copyright © 2010 SuZhou Yacoo Science Co., Ltd All Rights Reserved Powered by: Founder International
Yacoo Information Management Platform   用户登录   站内地图